Literature DB >> 1376715

A single human monoclonal antibody that confers total protection from tetanus.

B Arunachalam1, S Ghosh, G P Talwar, R Raghupathy.   

Abstract

Protective human monoclonal antibodies (HuMAbs) are superior to hyperimmune sera and murine monoclonal antibodies as far as human immunotherapy is concerned. In this report, we describe the successful generation of triomas secreting HuMAbs to tetanus toxin (tt). Lymphoblastoid cell lines secreting anti-tt antibodies were stabilized by back-fusion with a mouse x human heterohybrid myeloma partner, SBC-H20. One of the antibodies so produced, confers total protection of mice from tetanus, unlike a few recent reports where only partial protection (delay in the onset of tetanus) was achieved with single HuMAbs. Experiments to localize the neutralizing epitope(s) of the toxin using the protective monoclonal antibodies revealed that the antibody recognizes a conformational determinant that is destroyed on SDS-treatment. Preliminary studies show that Fab preparations of the protective antibody are capable of neutralizing tetanus toxin, suggesting that it might be possible to clone and express the Fab in a stable vector for large scale production.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376715     DOI: 10.1089/hyb.1992.11.165

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  4 in total

1.  Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies.

Authors:  Mehdi Yousefi; Roya Khosravi-Eghbal; Ahmad Reza Mahmoudi; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Fazel Shokri
Journal:  Hum Vaccin Immunother       Date:  2013-10-14       Impact factor: 3.452

2.  Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.

Authors:  D E Akiyoshi; C M Rich; S O'Sullivan-Murphy; L Richard; J Dilo; A Donohue-Rolfe; A S Sheoran; S Chapman-Bonofiglio; S Tzipori
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Novel neutralizing human monoclonal antibodies against tetanus neurotoxin.

Authors:  Takeharu Minamitani; Karin Kiyose; Ryota Otsubo; Toshihiro Ito; Hiroki Akiba; Rika A Furuta; Tsuyoshi Inoue; Kouhei Tsumoto; Masahiro Satake; Teruhito Yasui
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

Review 4.  Peptide-Based Vaccines: Current Progress and Future Challenges.

Authors:  Ryan J Malonis; Jonathan R Lai; Olivia Vergnolle
Journal:  Chem Rev       Date:  2019-12-05       Impact factor: 60.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.